Traditional bispecific antibody production (e.g. amivantamab) relies on the co-culture of two different cell types expressing half of the light-heavy chain of the antibody, and the subsequent dimerization of the half antibody secreted by the two cell types.
Due to the complicated production process:
The therapy cost of traditional bispecific antibody is very high
Ranging from USD 30,000 to USD 170,000 per treatment, which is barely affordable to most patients